X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Aurobindo Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs AUROBINDO PHARMA - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB AUROBINDO PHARMA DR. REDDYS LAB/
AUROBINDO PHARMA
 
P/E (TTM) x 29.9 14.6 204.3% View Chart
P/BV x 2.9 3.8 78.0% View Chart
Dividend Yield % 0.9 0.4 222.0%  

Financials

 DR. REDDYS LAB   AUROBINDO PHARMA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-17
AUROBINDO PHARMA
Mar-17
DR. REDDYS LAB/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs3,397895 379.5%   
Low Rs2,560622 411.6%   
Sales per share (Unadj.) Rs856.5254.6 336.4%  
Earnings per share (Unadj.) Rs78.039.3 198.5%  
Cash flow per share (Unadj.) Rs139.946.6 300.4%  
Dividends per share (Unadj.) Rs20.002.50 800.0%  
Dividend yield (eoy) %0.70.3 203.7%  
Book value per share (Unadj.) Rs739.8160.0 462.5%  
Shares outstanding (eoy) m165.74585.88 28.3%   
Bonus/Rights/Conversions BBESOP-  
Price / Sales ratio x3.53.0 116.7%   
Avg P/E ratio x38.219.3 197.8%  
P/CF ratio (eoy) x21.316.3 130.7%  
Price / Book Value ratio x4.04.7 84.9%  
Dividend payout %25.76.4 403.1%   
Avg Mkt Cap Rs m493,632444,390 111.1%   
No. of employees `00022.714.0 162.2%   
Total wages/salary Rs m31,06817,678 175.7%   
Avg. sales/employee Rs Th6,259.010,667.8 58.7%   
Avg. wages/employee Rs Th1,369.81,264.3 108.3%   
Avg. net profit/employee Rs Th569.71,645.8 34.6%   
INCOME DATA
Net Sales Rs m141,961149,157 95.2%  
Other income Rs m1,7151,159 148.0%   
Total revenues Rs m143,676150,316 95.6%   
Gross profit Rs m24,72234,343 72.0%  
Depreciation Rs m10,2664,276 240.1%   
Interest Rs m634667 95.0%   
Profit before tax Rs m15,53730,558 50.8%   
Minority Interest Rs m050 0.0%   
Prior Period Items Rs m3490-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,9657,597 39.0%   
Profit after tax Rs m12,92123,012 56.1%  
Gross profit margin %17.423.0 75.6%  
Effective tax rate %19.124.9 76.8%   
Net profit margin %9.115.4 59.0%  
BALANCE SHEET DATA
Current assets Rs m96,83792,062 105.2%   
Current liabilities Rs m84,19966,223 127.1%   
Net working cap to sales %8.917.3 51.4%  
Current ratio x1.21.4 82.7%  
Inventory Days Days73106 69.2%  
Debtors Days Days9868 144.3%  
Net fixed assets Rs m102,55262,919 163.0%   
Share capital Rs m829586 141.5%   
"Free" reserves Rs m121,79293,133 130.8%   
Net worth Rs m122,62193,719 130.8%   
Long term debt Rs m5,4491,814 300.4%   
Total assets Rs m218,165162,494 134.3%  
Interest coverage x25.546.8 54.5%   
Debt to equity ratio x00 229.6%  
Sales to assets ratio x0.70.9 70.9%   
Return on assets %6.214.6 42.6%  
Return on equity %10.524.6 42.9%  
Return on capital %12.932.7 39.4%  
Exports to sales %54.60-   
Imports to sales %9.40-   
Exports (fob) Rs m77,520NA-   
Imports (cif) Rs m13,274NA-   
Fx inflow Rs m81,67075,838 107.7%   
Fx outflow Rs m26,35530,224 87.2%   
Net fx Rs m55,31545,613 121.3%   
CASH FLOW
From Operations Rs m21,44432,786 65.4%  
From Investments Rs m-18,404-17,870 103.0%  
From Financial Activity Rs m-3,692-19,153 19.3%  
Net Cashflow Rs m-1,144-4,239 27.0%  

Share Holding

Indian Promoters % 25.5 54.1 47.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 8.0 67.9%  
FIIs % 35.3 27.7 127.4%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 10.2 150.0%  
Shareholders   75,885 69,601 109.0%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   PLETHICO PHARMA  BIOCON LTD  FULFORD INDIA  ALKEM LABORATORIES  AJANTA PHARMA  

Compare DR. REDDYS LAB With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Feb 23, 2018 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS